title: Pharmacokinetics of danofloxacin and N-desmethyldanofloxacin in adult horses and their concentration in synovial fluid.
abstract: The objectives of this study were to investigate the pharmacokinetics of danofloxacin and its metabolite N-desmethyldanofloxacin and to determine their concentrations in synovial fluid after administration by the intravenous, intramuscular or intragastric routes. Six adult mares received danofloxacin mesylate administered intravenously (i.v.) or intramuscularly (i.m.) at a dose of 5 mg/kg, or intragastrically (IG) at a dose of 7.5 mg/kg using a randomized Latin square design. Concentrations of danofloxacin and N-desmethyldanofloxacin were measured by UPLC-MS/MS. After i.v. administration, danofloxacin had an apparent volume of distribution (mean ± SD) of 3.57 ± 0.26 L/kg, a systemic clearance of 357.6 ± 61.0 mL/h/kg, and an elimination half-life of 8.00 ± 0.48 h. Maximum plasma concentration (Cmax ) of N-desmethyldanofloxacin (0.151 ± 0.038 μg/mL) was achieved within 5 min of i.v. administration. Peak danofloxacin concentrations were significantly higher after i.m. (1.37 ± 0.13 μg/mL) than after IG administration (0.99 ± 0.1 μg/mL). Bioavailability was significantly higher after i.m. (100.0 ± 12.5%) than after IG (35.8 ± 8.5%) administration. Concentrations of danofloxacin in synovial fluid samples collected 1.5 h after administration were significantly higher after i.v. (1.02 ± 0.50 μg/mL) and i.m. (0.70 ± 0.35 μg/mL) than after IG (0.20 ± 0.12 μg/mL) administration. Monte Carlo simulations indicated that danofloxacin would be predicted to be effective against bacteria with a minimum inhibitory concentration (MIC) ≤0.25 μg/mL for i.v. and i.m. administration and 0.12 μg/mL for oral administration to maintain an area under the curve:MIC ratio ≥50.
authors.affiliation: Department of Large Animal Medicine, University of Georgia, Athens, GA, USA.
authors.forename: B S
authors.initials: BS
authors.lastname: Lopez
authors.forename: S
authors.initials: S
authors.lastname: Giguère
authors.forename: L J
authors.initials: LJ
authors.lastname: Berghaus
authors.forename: M A
authors.initials: MA
authors.lastname: Mullins
authors.forename: J L
authors.initials: JL
authors.lastname: Davis
mesh_terms: D000818:Animals; D019540:Area Under Curve; D001682:Biological Availability; D005260:Female; D024841:Fluoroquinolones / Q000097:blood / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics*; D006207:Half-Life; D006736:Horses / Q000097:blood*; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D015363:Quinolones / Q000097:blood / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics*; D013582:Synovial Fluid / Q000737:chemistry*
chemical_list: D024841:Fluoroquinolones; D015363:Quinolones; C099500:N-desmethyldanofloxacin; C068581:danofloxacin